Skip to main content

Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: the OMERACT 9 v2 criteria.

Publication ,  Journal Article
Maksymowych, WP; Landewé, R; Tak, P-P; Ritchlin, CJ; Ostergaard, M; Mease, PJ; El-Gabalawy, H; Garnero, P; Gladman, DD; Fitzgerald, O; Boers, M ...
Published in: J Rheumatol
August 2009

OBJECTIVES: A draft set of criteria for the validation of soluble biomarkers reflecting damage endpoints was proposed at OMERACT 8. At OMERACT 9 we aimed to scrutinize the necessity for each of these criteria according to the objectives of the working group. METHODS: The OMERACT 8 draft criteria and the principle objectives of the validation process were clarified at a meeting of the working group in London, December 2007. A new framework was proposed after the following steps were conducted: (A) A systematic review of the literature focusing on the draft criteria and a preselected group of biomarkers (MMP3, CTX-II, RANKL, OPG, CTX-I) followed by a Delphi consensus exercise addressing the importance of individual criteria and identification of omissions in the draft set. (B) Formal debate as well as group discussion centered on the key arguments for inclusion/exclusion of specific criteria. (C) Onsite interactive electronic voting on the importance of specific criteria. The framework was presented and discussed at OMERACT 9 in both breakout and plenary sessions followed by a vote on its acceptance. RESULTS: The objectives of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis biomarkers in relation to their predictive validity for damage endpoints was clarified and supported by OMERACT 9 participants. The OMERACT 8 draft validation criteria were reformulated into an essential category focused on criteria addressing the OMERACT Filter elements of discrimination (incorporating truth) and feasibility, and a desirable but nonessential category of other criteria addressing truth. This revised draft set was endorsed by participants at OMERACT 9. CONCLUSION: A revised set of validation criteria has been drafted by consensus at OMERACT 9 that focuses on the performance characteristics of biomarker assays, the importance of addressing potential confounders, and the essential requirement for clinical validation studies.

Duke Scholars

Published In

J Rheumatol

DOI

ISSN

0315-162X

Publication Date

August 2009

Volume

36

Issue

8

Start / End Page

1785 / 1791

Location

Canada

Related Subject Headings

  • Spondylarthritis
  • Reproducibility of Results
  • Predictive Value of Tests
  • Joints
  • Humans
  • Biomarkers
  • Arthritis, Rheumatoid
  • Arthritis, Psoriatic
  • Arthritis & Rheumatology
  • Arthritis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Maksymowych, W. P., Landewé, R., Tak, P.-P., Ritchlin, C. J., Ostergaard, M., Mease, P. J., … van der Heijde, D. (2009). Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: the OMERACT 9 v2 criteria. J Rheumatol, 36(8), 1785–1791. https://doi.org/10.3899/jrheum.090346
Maksymowych, Walter P., Robert Landewé, Paul-Peter Tak, Christopher J. Ritchlin, Mikkel Ostergaard, Philip J. Mease, Hani El-Gabalawy, et al. “Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: the OMERACT 9 v2 criteria.J Rheumatol 36, no. 8 (August 2009): 1785–91. https://doi.org/10.3899/jrheum.090346.
Maksymowych WP, Landewé R, Tak P-P, Ritchlin CJ, Ostergaard M, Mease PJ, El-Gabalawy H, Garnero P, Gladman DD, Fitzgerald O, Aletaha D, Bykerk VP, Bathon JM, Syversen SW, Boers M, Geusens P, Inman RD, Kraus VB, Kvien TK, Taylor WJ, Wells GA, van der Heijde D. Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: the OMERACT 9 v2 criteria. J Rheumatol. 2009 Aug;36(8):1785–1791.

Published In

J Rheumatol

DOI

ISSN

0315-162X

Publication Date

August 2009

Volume

36

Issue

8

Start / End Page

1785 / 1791

Location

Canada

Related Subject Headings

  • Spondylarthritis
  • Reproducibility of Results
  • Predictive Value of Tests
  • Joints
  • Humans
  • Biomarkers
  • Arthritis, Rheumatoid
  • Arthritis, Psoriatic
  • Arthritis & Rheumatology
  • Arthritis